There is a loss of time for patient care and a huge increase in time burden outside the visit for doctors and pharmacists. Another major insurance change coming next year will affect another large swath of Dushays patients: In January, BCBS Massachusetts will be excluding all GLP-1s from coverage for treatment of obesity, reserving coverage for these drugs only when indicated to treat type 2 diabetes
Understanding how these medications work helps you prepare for future options
Myth #11: Its Not FDA Approved So It Must Be Unsafe The Claim: Retatrutide isnt approved yet which proves its dangerous, thats why FDA wont approve it (Facebook comment) The Reality: FDA approval status reflects where in the approval process a medication sits, not a safety judgment
Combined with healthy nutrition, regular physical activity, quality sleep, and ongoing medical guidance, retatrutide may help support meaningful and sustainable weight-loss results
Extrapolating from short-term obesity trial data to prolonged use in athletes is scientifically unjustifiable